We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 17.75 | 17.50 | 18.00 | 17.75 | 17.75 | 17.75 | 58,159 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.25 | 16.19M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/11/2017 14:30 | Shrewdie - guessing they are your delayed buys? | primal123 | |
14/11/2017 14:27 | Very encouraging.... | bobdown2 | |
14/11/2017 14:26 | MMs are way behind the curve. Personally still think this can 10 bag from here over next 24 months. Sort of puts us in the ball park with SOHs vision Ready to pop..... PS, dont care if I am ramping a little :-) | zebbo | |
14/11/2017 14:25 | no just delayed buys starting to show from earlier this pm. | shrewdmole | |
14/11/2017 14:19 | News leak....... | bobdown2 | |
14/11/2017 14:13 | definitely looks like games being played here - someone suggested an order to be filled and looks increasingly likely. | malreid | |
14/11/2017 14:09 | delayed buys to show. | shrewdmole | |
14/11/2017 14:09 | Ha ha, you've said it Rathean. Already on it's way back down! J | 2350220 | |
14/11/2017 14:00 | #malreid hush! Don't spook the MMs otherwise we'll see it dragged back to 70 :/ | rathean | |
14/11/2017 14:00 | Weird - the buying/selling doesn't seem to suggest the big step-up in share price - must be something going on behind the scenes. Any theories? | jestercat2 | |
14/11/2017 13:53 | Something spooked the price. | the drewster | |
14/11/2017 13:53 | mmm whats going on here? Bid and Offer rising nicely | malreid | |
14/11/2017 13:45 | That chart is itching to break out, surely over the next few trading days. A piece of really good news should do it! | parob | |
14/11/2017 11:22 | YAY! Someone just bought 500 shares! :p | loungeact | |
14/11/2017 08:57 | Sweetbiotix is slowly looming up under the radar......and the prospects for all four divisions increasing.....nice. | bobdown2 | |
14/11/2017 07:56 | In order to get some peoples blood pressure to that 130/80, the conventional drugs needed to achieve this can put a huge strain on the kidneys... which also happens to be life threatening...... any more ideas?!! | nicktopten | |
13/11/2017 23:31 | Tomorrow's New York Times: Under New Guidelines, Millions of Americans Will Need to Lower Blood Pressure Tens of millions more Americans will qualify for a diagnosis of high blood pressure, and will need to change their lifestyles or take medicines for the condition, under new medical guidelines released on Monday. Now, high blood pressure, or hypertension, will be defined as 130/80 millimeters of mercury or greater for anyone with a significant risk of heart attack or stroke. By those criteria, nearly half of all American adults, and nearly 80 percent of those aged 65 and older, will need to take steps to reduce their blood pressure. Any suggestions on what could help? | parob | |
13/11/2017 22:50 | Wow Parob, what an article! It really does feel to me, that we are at the very start of a massive transformational shift in potential treatments for all manner of ailments. I was thinking, if we can use modulated microbiome to Improve our immune system, could we then possibly use a differently modulated microbiome to Reduce people's immune system? My wife, and many people we know, has had a transplant (heart & lungs), and as such will always have to take anti rejection drugs (which are designed to Lower the patient's immunity). ALL of the anti rejection drugs I know of, are actually Toxic, especially to the patient's kidneys. So much so, that we know of several folk who've had heart transplants, have gone on to need kidney transplants down the line. IF we could develop microbiome based anti rejection/lower immunity, that would instantly reduce the many many side effects associated with these drugs. If you think that this is a bit Niche, just think how many people have had organ transplants (not just hearts), and then ALL of these people have to take anti rejection drugs morning and night . . . Every day of the rest of their lives. A ready made ongoing market. Just a few thoughts. John | 2350220 | |
13/11/2017 21:24 | PGlancy - The trades (0-C) we often see at the beginning of the days trades for the same value and quantity at the same price are usually a buy and a sell facilitated by the same broker for 2 different clients, hence why they have no impact on the share price either way. | elrico | |
13/11/2017 18:06 | Mainstream media coverage of the microbiome really picking up. This past week alone has seen articles in the Guardian, The Economist and NY Times: LPLDL recent tweet: The microbiome word is getting out there, check out New York Times great article explaining how it can benefit your health One can only imagine the coverage we’ll receive once the Sweetbiotix story gets picked up. Really hope they float that division on the Nasdaq! | parob | |
13/11/2017 16:33 | Much better late price for my 15000 at the close. | aspex | |
13/11/2017 16:19 | "Game Changer" :) | judijudi | |
13/11/2017 16:04 | No biggie Elrico and I am actually in the same boat as you. The two year stagnation has allowed me to accumulate way more shares than I ever thought I'd be able to. I continue to suck up the short term pain for the inevitable(!) long term gain. | shazbo | |
13/11/2017 15:47 | Exactly Lounge! | primal123 | |
13/11/2017 15:46 | Yes it is difficult to trade, but if someone can do this then fair play to them! Anyway let's hope we hear some more news soon as I will be glad to get out of this range! | primal123 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions